ORIGINAL INVESTIGATION

Association Between Pulmonary Fibrosis and Coronary Artery Disease

Jorge R. Kizer, MD, MSc; David A. Zisman, MD; Nancy P. Blumenthal, MSN, CRNP; Robert M. Kotloff, MD; Stephen E. Kimmel, MD, MS; Robert M. Strieter, MD; Selim M. Arcasoy, MD; Victor A. Ferrari, MD; John Hansen-Flaschen, MD

Background: Pulmonary fibrosis and atherosclerosis have many similarities at the histopathologic level. Moreover, fibrotic lung diseases exhibit systemic effects and have the potential to affect the vasculature beyond the lung. The existence of a relationship between the two, however, has not been studied.

Methods: To investigate whether fibrotic lung disorders may predispose to atherosclerosis, we conducted a cross-sectional study of 630 patients referred for lung transplantation evaluation at a university hospital. We compared the prevalence of angiographic coronary artery disease (CAD) in patients with fibrotic vs nonfibrotic lung diseases.

Results: Fibrotic lung diseases were associated with an increased prevalence of CAD compared with nonfibrotic diseases after adjustment for traditional risk factors (odds ratio, 2.18; 95% confidence interval, 1.17-4.06). The magnitude and significance of this association were maintained when only nongranulomatous fibrotic disease or its subset, idiopathic pulmonary fibrosis, was examined. The strength of the relationship between fibrotic disorders and CAD increased when multivessel disease was analyzed (odds ratio, 4.16; 95% confidence interval, 1.46-11.9). No significant association was detected for granulomatous fibrotic disorders (odds ratio, 1.56; 95% confidence interval, 0.47-5.16; $P=.47$), although this subgroup had fewer cases of CAD for analysis.

Conclusions: These findings support an association between fibrotic lung disorders and CAD. Further research is necessary to confirm this relationship and to explore the pathologic processes underlying, and potentially linking, these 2 conditions.

Arch Intern Med. 2004;164:551-556

Atherosclerosis results from an excessive inflammatory and/or fibroproliferative response to various insults to the endothelium and smooth muscle of the arterial wall.[1] The pathogenesis of the atherosclerotic lesion involves recruitment of leukocytes into the vascular intima, accumulation of cholesterol-laden mononuclear cells, vascular smooth muscle cell proliferation and migration, deposition of collagen-rich extracellular matrix, and neovascularization to support the evolving fibroproliferative process.[1]

Fibrotic lung diseases have many pathologic parallels to atherosclerosis.[1] In these heterogeneous disorders, there is also recruitment of leukocytes into the pulmonary compartment, destruction of alveolar-capillary units by the inflammatory process, and subsequent stimulation of pulmonary myofibroblasts to produce extracellular matrix.[2,3] New blood vessel formation similarly supports myofibroblast activity, leading to the replacement of functional lung parenchyma by fibrous tissue.[2,3]

The pathologic similarities between these 2 conditions suggest that they could be linked. Furthermore, the finding of elevated proinflammatory factors[4-6] and acute phase reactants[4,7] in the sera of patients with fibrotic lung diseases provides potential mechanisms through which these disorders could promote atherogenesis. To our knowledge, the relationship between pulmonary fibrosis and atherosclerosis has not been explored. We examined a cohort of patients with end-stage lung disease to investigate whether fibrotic lung disorders may predispose to coronary artery disease (CAD).

METHODS

STUDY POPULATION

The study population included all consecutive patients evaluated for lung transplantation at the Hospital of the University of Pennsylvania in whom coronary angiography was performed between July 1, 1992, and December 31, 2000. Two investigators (J.R.K., D.A.Z.) abstracted relevant data from detailed clinical forms completed for each patient at the time of transplantation evaluation. Patients referred to the clinic

The author affiliations are listed and the end of this article.
The authors have no relevant financial interest in this article.

©2004 American Medical Association. All rights reserved.

Downloaded From: http://archinte.jamanetwork.com/ on 11/29/2015

because of chronic rejection of a previous lung transplant or radiation-induced pulmonary fibrosis were excluded. Coronary angiography was performed routinely in patients older than 40 years. In younger patients with coronary risk factors, angiography was ordered at the discretion of the transplantation pulmonologist. Patients with cystic fibrosis, who were generally too young to undergo angiography, were also excluded from analysis.

CLASSIFICATION OF LUNG DISORDERS

The fibrotic lung disorders category comprised all patients diagnosed as having fibrosing interstitial lung disease at the time of evaluation. Interstitial lung disease is a diverse group of disorders characterized by varying degrees of interstitial inflammation and fibroproliferation.[8] The extent to which the pathologic process leads to fibrotic replacement of the lung parenchyma is highly variable. In our population, however, equation of interstitial lung disease with pulmonary fibrosis was justified because these diseases had progressed to diffuse, end-stage fibrosis. The reference category, nonfibrotic disorders, consisted of patients with diseases in which fibroproliferation is not a dominant pathogenetic feature, mainly disorders of the airways and pulmonary vasculature. Patients with pulmonary fibrosis were subdivided into nongranulomatous and granulomatous categories on the basis of their evaluation diagnosis, and the former group was further categorized into an idiopathic pulmonary fibrosis (IPF) subset. To ensure a classification of IPF consistent with the currently accepted clinicopathologic system,[9] 3 pulmonologists (D.A.Z., R.M.K., and S.M.A.) reviewed the primary medical records of all patients with nongranulomatous interstitial lung disease and revised the evaluation form diagnoses by consensus.

DEFINITION OF POTENTIAL CONFOUNDING FACTORS

The following definitions were used for various potential confounding factors: *hypertension* is a history of documented high blood pressure (≥140/90 mm Hg) or treatment with antihypertensive medication; *hypercholesterolemia* is a serum total cholesterol level of 240 mg/dL or higher (≥6.21 mmol/L) or use of lipid-lowering therapy; *glucose intolerance* is a fasting serum glucose level of 140 mg/dL or greater (≥7.8 mmol/L) or a random serum glucose level of 200 mg/dL or greater (≥11.1 mmol/L) or use of oral hypoglycemic or insulin therapy (if receiving systemic glucocorticoid therapy, during maintenance dosing only); *family history* is a history of CAD in a first-degree relative younger than 60 years; and *coexisting systemic inflammatory disease* is a diagnosis of collagen vascular disease, inflammatory bowel disease, or hepatic cirrhosis.

DEFINITION OF END POINTS

Coronary artery disease was defined as the presence of 1 or more 50% or greater stenoses in an epicardial coronary artery, as reported in the cardiac catheterization summary reviewed for each patient. The secondary end point of *multivessel CAD* was used to classify patients with 50% or greater lesions in 2 or more major epicardial vessel distributions. Patients with a documented history of CAD occurring before the radiographic detection or formal diagnosis of the pulmonary disorder prompting transplantation evaluation were excluded from analysis.

COMPARISONS

In the primary analysis, we compared the prevalence of CAD in fibrotic vs nonfibrotic lung disorders. Secondary analyses focused on subgroups of fibrotic disease. Granulomatous and nongranulomatous fibrosis—and the nongranulomatous subset, IPF—were each compared with nonfibrotic disorders. Where numbers were sufficient for analysis, similar comparisons were performed for multivessel CAD.

STATISTICAL ANALYSIS

Categorical variables are reported as percentages, and continuous variables are presented as medians and ranges. The χ^2 test or Fisher exact test and the Wilcoxon rank sum test were used in comparisons of categorical variables and nonnormally distributed continuous variables, respectively.

To control for confounding, we identified 11 covariates routinely documented in the transplantation evaluation forms that are established or potential risk factors for CAD, including the binary variables sex, race, hypercholesterolemia, hypertension, glucose intolerance, family history of premature CAD, coexisting systemic inflammatory disease, cytomegalovirus seropositivity, and oral glucocorticoid therapy; cigarette smoking as an interval variable by tertile of cumulative pack-years (≤20, 21-60, >60 pack-years); and age as a continuous variable. In the primary comparison, the number of outcomes permitted fitting a full logistic regression model containing the exposure plus all prespecified covariates. We then serially eliminated covariates whose removal resulted in the smallest changes in the magnitude of the odds ratio (OR) until no additional covariate could be dropped without altering this effect estimate by 10% or more. In the remaining analyses, fewer outcomes required building multivariable models through sequential addition of covariates. The 10% change-in-estimate cutoff value was again used, this time to identify univariable, and retain important multivariable, confounders for the final model. Covariate inclusion in the multivariable model continued until no single covariate capable of substantively affecting the OR could be added. Analyses were performed using SAS statistical software (SAS version 6.2; SAS Institute Inc, Cary, NC).

RESULTS

Of 694 study-eligible patients, 7 (4 with pulmonary fibrosis and 3 without) were excluded because clinical cardiac disease had predated the detection of lung disease. An additional 57 patients did not undergo coronary angiography, leaving 630 patients for analysis. Compared with this cohort, the no-angiography group was younger (median, 37 years; $P<.001$), more often female (68%; $P<.001$), smoked less (median, 0 pack-years; $P=.04$)), and had fewer remaining coronary risk factors (67% without hypertension, glucose intolerance, hypercholesterolemia, or a positive family history; $P=.002$). Eighty-four percent of patients not receiving angiography had nonfibrotic disorders vs 70% of those receiving angiography ($P=.03$).

Table 1 gives the distribution of pulmonary disorders in the study cohort. The clinical and demographic characteristics of patients with fibrotic vs nonfibrotic disorders are given in **Table 2**. In patients with fibrotic lung disorders, male sex, glucose intolerance, cytomegalovirus seropositivity, and use of oral glucocorticoids were significantly higher and white race, family history, and pack-years smoked were significantly lower. This was also the case for nongranulomatous fibrosis vs the reference group, except that coexisting inflammatory disease, but not family history, was significantly more prevalent in the nongranulomatous subset. In turn, the granulomatous subgroup was younger and had fewer whites, pack-years smoked, and positive family histories but more glucocorticoid therapy and glucose intolerance than the nonfibrotic group.

Figure 1 shows the prevalence of CAD in the various lung disease groups. Coronary artery disease was most prevalent in the nongranulomatous subgroup and least

©2004 American Medical Association. All rights reserved.

Downloaded From: http://archinte.jamanetwork.com/ on 11/29/2015

frequent in the granulomatous subgroup. In the case of coronary revascularization for critical CAD, the higher rate observed for nongranulomatous fibrosis relative to the reference group proved to be statistically significant (3.6% vs 0.7%; $P=.03$).

The crude and adjusted ORs of CAD for fibrotic vs nonfibrotic disorders are given in **Table 3**. No significant crude relationship was observed with the primary end point of any CAD. Adjustment for smoking, however, yielded a statistically significant association between fibrotic disorders and CAD. This relationship remained significant after multivariable adjustment for the aggregate of measured confounding (OR, 2.18; 95% confidence interval [CI], 1.17-4.06). A stronger relationship was observed in the analysis of multivessel CAD, which also proved significant in the smoking-adjusted comparison and the multivariable-adjusted comparison (OR, 4.16; 95% CI, 1.46-11.9).

In **Table 4**, the nongranulomatous fibrosis subgroup is compared with the nonfibrotic group. There was a significant association for any CAD and multivessel disease after multivariable adjustment. The magnitude of the association with CAD was slightly greater than that observed in the primary comparison (OR, 2.37; 95% CI, 1.22-4.60), and that for multivessel disease was again close to twice as large as for any CAD. Further analyses also showed a significant association between IPF and CAD after multivariable adjustment (OR, 2.31; 95% CI, 1.11-4.82). In contrast, there was no significant association between granulomatous fibrosis and CAD (OR, 1.56; 95% CI, 0.47-5.16). Multivariable-adjusted ORs of CAD for fibrotic lung disorders and its subsets are summarized in **Figure 2**.

Table 1. Pulmonary Diagnoses in the Study Cohort

Pulmonary Diagnosis	Patients, No. (%) (N = 630)
Fibrotic disorders	
Nongranulomatous ILD	
IPF/primary UIP	76 (12.1)
Other idiopathic interstitial pneumonia*	12 (1.9)
CVD associated†	14 (2.2)
Pneumoconiosis (asbestos/silica)	5 (0.8)
Drug induced	2 (0.3)
Other secondary interstitial pneumonia‡	4 (0.6)
Subtotal	**113 (17.9)**
Granulomatous ILD	
Sarcoidosis	58 (9.2)
Hypersensitivity pneumonitis	9 (1.4)
Langerhans cell histiocytosis	5 (0.8)
Chronic berylliosis	1 (0.2)
Subtotal	**73 (11.6)**
Subtotal	**186 (29.5)**
Nonfibrotic disorders	
COPD	
Emphysema/chronic bronchitis/asthma	330 (52.4)
A1AD	39 (6.2)
Bronchiectasis	10 (1.6)
Subtotal	**379 (60.2)**
Pulmonary hypertension§	56 (8.9)
Lymphangioleiomyomatosis	8 (1.3)
Obliterative bronchiolitis	1 (0.2)
Subtotal	**444 (70.5)**

Abbreviations: AIAD, α1-antitrypsin deficiency; COPD, chronic obstructive pulmonary disease; CVD, collagen vascular disease; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; UIP, usual interstitial pneumonia.

*Includes desquamative interstitial pneumonia, nonspecific interstitial pneumonia, respiratory bronchiolitis interstitial pneumonia, and unclassified.

†Includes secondary UIP, nonspecific interstitial pneumonia, and bronchiolitis obliterans organizing pneumonia.

‡Includes post–acute respiratory distress syndrome and alveolar microlithiasis.

§Primary or secondary.

COMMENT

In this study, we found a strong association between fibrotic lung disorders and CAD after adjusting for multiple coronary risk factors. This association remained significant and consistent in magnitude in the subgroup with nongranulomatous fibrosis. It was also maintained in the subset with IPF, which constituted a large proportion of the patients in the nongranulomatous category. For fibrotic lung disorders and the nongranulomatous subgroup, the association became more pronounced when multivessel CAD was used as the outcome measure. By contrast, we could not demonstrate a significant association for the subgroup with granulomatous fibrosis. The observed effect in the latter was also positive, but it was surrounded by broad confidence bounds. In the granulomatous subgroup, younger age, lower cigarette consumption, and less frequent family history may have contributed to the smaller end point prevalence. Removal of this subgroup, in fact, led to small increases in the associations found for the nongranulomatous and IPF subsets. Our data, however, cannot establish whether the lack of a significant association for granulomatous fibrotic processes stems exclusively from these factors, reflects the weaker association between these diseases themselves and CAD, or is a mixture of these and other factors.

The observed association between fibrotic lung disorders and CAD emerged only after correction for differences in the distribution of coronary risk factors. Cumulative exposure to tobacco was markedly higher in the reference category, reflecting the predominance of smoking-related emphysema in this group. Accordingly, smoking constituted the principal confounder of the association. Correction for its effect on CAD prevalence in the nonfibrotic cohort unmasked the significantly higher prevalence of CAD in the fibrotic lung disorders group.

Neither glucose intolerance nor glucocorticoid therapy, each a traditional risk factor that was more frequent in the pulmonary fibrosis group, was identified as a significant multivariable confounder. Our inability to adjust for cumulative glucocorticoid dose leaves open the possibility of residual confounding. However, glucocorticoids are believed to predispose to atherosclerosis mainly through their indirect effects on other cardiovascular risk factors,[10] most of which were controlled for in the analysis. Thus, the extent of residual confounding by this factor, if any, is likely to have been minimal.

The association described reflects the use of patients with nonfibrosing lung diseases as the reference category. The strength of the association might have differed had the comparisons been performed with adults free of lung disease. Nevertheless, patients with chronic obstructive pulmonary disease may be at increased risk of CAD,[11,12] suggesting that the association might have been stronger had healthy individuals constituted the reference group.

©2004 American Medical Association. All rights reserved.

Downloaded From: http://archinte.jamanetwork.com/ on 11/29/2015

Table 2. Clinical and Demographic Characteristics of 630 Patients With Fibrotic vs Nonfibrotic Disorders

Characteristic	Fibrotic Disorders (n = 186)			Nonfibrotic Disorders (n = 444)	*P* Value		
	Total	NG (n = 113)	G (n = 73)		Fibrotic vs Nonfibrotic	NG vs Nonfibrotic	G vs Nonfibrotic
Age, median (range), y	51 (27-65)	55 (28-65)	49 (27-63)*	54 (19-66)	.06	.27	<.001
Male, %	52.2†	60.2*	39.7	43.0	.04	.001	.60
White, %	65.1*	81.4*	39.7*	92.6	<.001	<.001	<.001
Hypertension, %	23.7	16.8	34.2	24.3	.86	.09	.07
Hypercholesterolemia, %	33.1	32.7	33.8	35.0	.66	.66	.85
Total cholesterol level, median (range), mg/dL	207 (108-317)	208 (127-317)	206 (108-312)	220 (85-405)	.11	.32	.13
Glucose intolerance, %	17.2*	14.2*	21.9*	4.1	<.001	<.001	<.001
Smoking, median (range), pack-years	10 (0-111)*	18 (0-111)*	1 (0-105)*	40 (0-200)	<.001	<.001	<.001
Family history, %	7.1†	8.9	4.2†	13.1	.03	.23	.03
Coexisting inflammatory disease, %‡	5.9	8.8§	1.4	3.6	.19	.02	.32
CMV seropositive, %	65.2§	65.8†	64.3	54.3	.01	.03	.12
Oral glucocorticoid use, %	73.7*	70.8*	78.1*	45.5	<.001	<.001	<.001

Abbreviations: CMV, cytomegalovirus; G, granulomatous; NG, nongranulomatous.
SI conversion factor: To convert total cholesterol to millimoles per liter, multiply by 0.02586.
*$P \leq .001$ vs the nonfibrotic group.
†$P < .05$ vs the nonfibrotic group.
‡Includes collagen vascular disease, inflammatory bowel disease, and hepatic cirrhosis.
§$P \leq .01$ vs nonfibrotic group.



Figure 1. Prevalence of coronary artery disease (CAD) in the various lung disease groups. Revascularization consisted of percutaneous coronary intervention or coronary bypass surgery (performed at any time after detection of pulmonary disease). G indicates granulomatous; NG, nongranulomatous.

Table 3. Coronary Artery Disease in Fibrotic vs Nonfibrotic Disorders

Variable	Odds Ratio (95% CI)	*P* Value
Any CAD		
Crude	1.19 (0.70-2.02)	.53
Age adjusted	1.29 (0.75-2.22)	.35
Smoking adjusted	1.83 (1.02-3.28)	.04
Multivariable adjusted*	2.18 (1.17-4.06)	.01
Multivessel CAD		
Crude	2.04 (0.86-4.80)	.10
Age adjusted	2.21 (0.93-5.23)	.07
Smoking adjusted	3.35 (1.31-8.61)	.01
Multivariable adjusted†	4.16 (1.46-11.9)	.008

Abbreviations: CAD, coronary artery disease; CI, confidence interval.
*Adjusted for age, race, smoking, and family history. Model inclusion of sex, hypertension, hypercholesterolemia, glucose intolerance, oral glucocorticoid use, coexisting inflammatory disease, and cytomegalovirus seropositivity, either individually or in combination, did not substantially modify the odds ratio.
†Adjusted for glucose intolerance, smoking, family history, and cytomegalovirus positivity. Model inclusion of age, sex, race, hypertension, hypercholesterolemia, oral glucocorticoid use, and coexisting inflammatory disease did not substantially modify the odds ratio.

POTENTIAL BIOLOGICAL BASIS FOR ASSOCIATION

Three explanations may be advanced to account for the association reported herein. One possibility is that a common offending agent gives rise to both processes. A second is the presence of a general proclivity to fibrosis in response to the same or different stimuli in affected individuals. The third is that the 2 processes could be linked by a causal relationship.

The first 2 explanations are suggested by similarities in the cellular pathologic features of atherosclerosis and chronic fibrosing lung diseases.[1] Both are thought to be initiated by local injury, which results in a sustained inflammatory response and eventuates in fibroproliferation.[1-3] In CAD, various epidemiologic risk factors can produce endothelial injury and atherosclerosis in animal models.[1] But as many as one half of patients with CAD may have no detectable clinical predisposition.[1,13] Similarly, whereas in some forms of fibrotic lung disease the injurious factor is well established,[8] for IPF and sarcoidosis the nature of the injurious stimulus remains undefined.[3,14] These unresolved questions have led to consideration of infectious etiologies, a notion bolstered in atherosclerosis by recent reports of significant associations with a variety of organisms.[13] However, the results of histopathologic studies[1,3] and analyses[3,15-17] of helper T-cell cytokine profiles show that the patterns of leukocyte involvement in pulmonary fibrosis and atherosclerosis are distinct. These important differences in immunologic response make it improbable that

©2004 American Medical Association. All rights reserved.

Downloaded From: http://archinte.jamanetwork.com/ on 11/29/2015

a single agent, or group of agents, could be involved in the pathogenesis of both. Together with the observation that patients with CAD do not often develop pulmonary fibrosis, such differences in immunologic response also argue against an inherent predisposition to fibrosis as the principal mechanism.

We favor the third explanation instead, that of a causal relationship wherein pulmonary fibrosis promotes atherosclerosis. Several lines of evidence suggest that the fibroproliferative lung process can exert systemic effects. Levels of cytokines and growth factors,[4-6] as well as biologically active eicosanoids,[18] have been found to be elevated in the sera or urine of patients with fibrosing lung diseases. The former have been implicated in the hepatic production of acute phase reactants in these disorders.[4,7] Circulating immune complexes also can be detected in the plasma of patients with IPF.[8] Furthermore, pulmonary fibrosis is associated with the development of vascular proliferation in the digits and mediastinum.[19] Hence, the fibroproliferative process seems to affect cells beyond the pulmonary compartment, and the many mediator molecules produced in these disorders[2,3] provide multiple potential mechanisms through which they might promote atherogenesis.

CANDIDATE MOLECULAR PATHWAYS

Present understanding of immune mediators allows us to speculate on several of the possible candidates. Among them, the cytokines interleukin (IL) 4, tumor necrosis factor α, and IL-13, all of which show elevated levels in pulmonary fibrosis, could lead to atherogenesis in a variety of ways. Interleukin 4 and tumor necrosis factor α can up-regulate cell adhesion molecules[20-22] that are central to the recruitment of leukocytes to the vascular intima.[1] Also, IL-4 and IL-13 can stimulate cellular lipoxygenases that generate proatherogenic oxidized low-density lipoprotein.[23,24] Moreover, IL-4 and IL-13 can reduce hyaluronectin secretion,[25] leading to lower levels of this angiogenesis-inhibiting molecule,[26] which could potentially have a proatherogenic effect.[27,28]

Another prospect is IL-8, a chemokine found in the serum of patients with IPF[5] and sarcoidosis[6] that has proved to be important in the angiogenesis underlying atherosclerotic plaque growth.[27,28] The notion of a circulating angiogenic factor in pulmonary fibrosis is appealing in light of the common finding of clubbing in IPF, sarcoid-associated fibrosis, and hypersensitivity pneumonitis.[29] Like pulmonary fibrosis and atherosclerosis, clubbing involves neovascularization and fibroplasia.[19,30] Although impaction of circulating megakaryocytes in digital capillaries can explain clubbing in many instances, it is probable that additional factors play a role, and circulating cytokines, including IL-8, remain attractive candidates.[31]

LIMITATIONS

A spurious association could have resulted in our population if the referral-for-transplantation threshold for patients with chronic obstructive pulmonary disease and CAD was higher than that for patients with fibrotic lung disorders. There are no clinical grounds to suspect that this would be the case. Alternatively, if patients with smoking-related emphysema underwent more frequent workup for the presence of CAD than patients with fibrotic lung disorders, leading to increased detection of CAD that would result in decisions not to refer for transplantation evaluation, this would reduce the prevalence of CAD among patients with chronic obstructive pulmonary disease in our study. Although we cannot entirely discount this possibility, the finding that the fibrosis and reference groups were balanced to most traditional risk factors, except for more smoking and family history in the latter, mitigates the concern that patients at higher risk were differentially excluded.

We did not adjust for high-density lipoprotein cholesterol levels because such data were unavailable. Whereas small studies[32,33] have documented elevated high-density lipoprotein levels in emphysema, larger studies[34,35] have not confirmed this finding. Regardless, it would be difficult to explain the magnitude of the associations with the primary, and especially the secondary, end point in this study solely on the basis of high-density lipoprotein concentration differences.

Table 4. Coronary Artery Disease in Nongranulomatous Fibrosis vs Nonfibrotic Disorders

Variable	Odds Ratio (95% CI)	*P* Value
Any CAD		
Crude	1.59 (0.89-2.87)	.12
Age adjusted	1.51 (0.83-2.75)	.18
Smoking adjusted	2.16 (1.16-4.04)	.01
Multivariable adjusted*	2.37 (1.22-4.60)	.01
Multivessel CAD		
Crude	2.37 (0.91-6.16)	.08
Age adjusted	2.22 (0.85-5.84)	.11
Smoking adjusted	3.66 (1.32-10.1)	.01
Multivariable adjusted†	4.42 (1.46-13.4)	.009

Abbreviations: CAD, coronary artery disease; CI, confidence interval.
*Adjusted for age, hypertension, smoking, and family history. Model inclusion of sex, race, hypercholesterolemia, glucose intolerance, oral glucocorticoid use, coexisting inflammatory disease, and cytomegalovirus seropositivity, either individually or in combination, did not substantially modify the odds ratio.
†Adjusted for smoking, glucose intolerance, family history, and cytomegalovirus seropositivity. Model inclusion of age, sex, race, hypertension, hypercholesterolemia, oral glucocorticoid use, and coexisting inflammatory disease did not substantially modify the odds ratio.



Figure 2. Multivariable-adjusted odds ratios (ORs) (logarithmic scale) and 95% confidence intervals (CIs) for coronary artery disease (CAD) in the various lung disease groups.

©2004 American Medical Association. All rights reserved.

Downloaded From: http://archinte.jamanetwork.com/ on 11/29/2015

Fifty-seven patients did not undergo coronary angiography. For most patients, this decision was based on age and risk factor prevalence, placing this group at lower likelihood of CAD than the study cohort. The excluded group, however, had a higher proportion of nonfibrotic lung diseases than the cohort that did undergo angiography. Thus, any bias resulting from exclusion of these patients would tend to underestimate the true difference in CAD prevalence between fibrotic and nonfibrotic disorders.

Last, the proposition that fibrotic lung disorders can promote atherosclerosis cannot be confirmed or refuted by a cross-sectional study design. Such a hypothesis can only be tested definitively through longitudinal follow-up, whether in experimental animal models or in human populations, with a clear assessment of incident atherosclerotic disease. Given that pulmonary fibrosis occurs at a relatively advanced stage in humans, pursuit of an epidemiologic study of this kind may be currently infeasible. The association reported herein is an important initial step toward investigating such potential relationships. This investigation should provide impetus for further studies of fibrosing disorders of the lungs and other organ systems in an effort to better understand the inflammatory determinants of the atherosclerotic process and ways in which fibroproliferative disorders throughout the body might be related.

Accepted for publication April 24, 2003.

From the Division of Cardiology, Departments of Medicine and Public Health, Weill Medical College of Cornell University, New York, NY (Dr Kizer); the Pulmonary, Allergy, and Critical Care Division (Drs Zisman, Kotloff, and Hansen-Flaschen and Ms Blumenthal), the Cardiovascular Division, Department of Medicine (Drs Kimmel and Ferrari), and the Department of Epidemiology and Biostatistics, Center for Clinical Epidemiology and Biostatistics (Dr Kimmel), University of Pennsylvania School of Medicine, Philadelphia; the Division of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, Calif (Dr Strieter); and the Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Columbia University College of Physicians and Surgeons, New York (Dr Arcasoy). Dr Zisman is now with the Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA.

This study was presented in part in abstract form at the 23rd Congress of the European Society of Cardiology; September 3, 2001; Stockholm, Sweden.

We thank all the members of the Penn Lung Transplant Team for their unfailing dedication to the daily care of our patients.

Corresponding author and reprints: David A. Zisman, MD, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, CHS 37-131, PO Box 951690, Los Angeles, CA 90095-1690 (e-mail: dzisman@mednet.ucla.edu).

REFERENCES

1. Ross R. Atherosclerosis: an inflammatory disease. *N Engl J Med.* 1999;340:115-126.
2. Chan ED, Worthen GS, Augustin A, Lapadat R, Riches DWH. Inflammation in the pathogenesis of interstitial lung disease. In: Schwartz MI, King TE, eds. *Interstitial Lung Disease.* 3rd ed. Hamilton, Ontario: BC Decker Inc; 1998:135-164.
3. Strieter RM, Keane MP, Standiford TJ, Kunkel SL. Cytokine biology and the pathogenesis of interstitial lung disease. In: Schwartz MI, King TE, eds. *Interstitial Lung Disease.* 3rd ed. Hamilton, Ontario: BC Decker Inc; 1998:181-205.
4. Yamanouchi H, Fujita J, Yoshinouchi T, et al. Measurement of hepatocyte growth factor in serum and bronchoalveolar lavage fluid in patients with pulmonary fibrosis. *Respir Med.* 1998;92:273-278.
5. Ziegenhagen MW, Zabel P, Zissel G, Schlaak M, Muller-Quernheim J. Serum level of interleukin-8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity. *Am J Respir Crit Care Med.* 1998;157:762-768.
6. Yokoyama T, Kanda T, Kobayashi I, Suzuki T. Serum levels of interleukin-8 as a marker of disease activity in patients with chronic sarcoidosis. *J Med.* 1995;26:209-219.
7. Drent M, Wirnsberger RM, de Vries J, van Dieijen-Visser MP, Wouters EFM, Schols AMWJ. Association of fatigue with an acute phase response in sarcoidosis. *Eur Respir J.* 1999;13:718-722.
8. Schwartz MI. Approach to the understanding, diagnosis, and management of interstitial lung disease. In: Schwartz MI, King TE, eds. *Interstitial Lung Disease.* 3rd ed. Hamilton, Ontario: BC Decker Inc; 1998:3-30.
9. American Thoracic Society, European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. *Am J Respir Crit Care Med.* 2000;161:646-664.
10. Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. *Can J Cardiol.* 2000;16:505-511.
11. Jousilahti P, Vartianinen E, Tuomilehto J, Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. *Lancet.* 1996;348:567-572.
12. Wedzicha JA, Seemungal TAR, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. *Thromb Haemost.* 2000;84:210-215.
13. Muhlenstein JB. Chronic infection and coronary artery disease. *Med Clin North Am.* 2000;84:123-148.
14. American Thoracic Society, European Respiratory Society, World Association of Sarcoidosis and Other Granulomatous Disorders. Statement on sarcoidosis. *Am J Respir Crit Care Med.* 1999;160:736-755.
15. Uyemura K, Demer LL, Castle SC, et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. *J Clin Invest.* 1996;97:2130-2138.
16. Frostegard J, Ulfgren AK, Nyberg P, et al. Cytokine expression in advanced human atherosclerotic plaques. *Atherosclerosis.* 1999;145:33-43.
17. De Boer OJ, Van Der Wal AC, Verhagen CE, Becker AE. Cytokine secretion profiles of cloned T cells from human aortic atherosclerotic plaques. *J Pathol.* 1999;188:174-179.
18. Montuschi P, Ciabattoni G, Paredi P, et al. 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. *Am J Respir Crit Care Med.* 1998;158:1524-1527.
19. Turner-Warwick M. Systemic arterial patterns in the lung and clubbing of the fingers. *Thorax.* 1963;18:238-250.
20. Barks JL, McQuillan JJ, Iademarco MF. TNF-α and ILF-4 synergistically increase vascular cell adhesion molecule-1 expression in cultured vascular smooth muscle cells. *J Immunol.* 1997;159:4532-4538.
21. Iademarco MF, Barks JK, Dean DC. Regulation of vascular cell adhesion molecule-1 expression by IL-4 and TNF-α in cultured endothelial cells. *J Clin Invest.* 1995;95:264-271.
22. Khew-Goodall Y, Wadham C, Stein BN, Gamble JR, Vadas MA. Stat6 activation is essential for interleukin-4 induction of *P*-selectin transcription in human umbilical vein endothelial cells. *Arterioscler Thromb Vasc Biol.* 1999;19:1421-1429.
23. Natarajan R, Rosdahl J, Gonzales N, Bai W. Regulation of 12-lipoxygenase by cytokines in vascular smooth muscle cells. *Hypertension.* 1997;30:873-879.
24. Folcik VA, Aamir R, Cathcart MK. Cytokine modulation of LDL oxidation by activated human monocytes. *Arterioscler Thromb Vasc Biol.* 1997;17:1954-1961.
25. Girard N, Maingonnat C, Bertrand P, Vasse M, Delpech B. Hyaluronectin secretion by monocytes. *Cytokine.* 1999;11:579-584.
26. Trochon V, Mabilat-Pragnon C, Bertrand P, et al. Hyaluronectin blocks the stimulatory effect of hyaluronan-derived fragments on endothelial cells during angiogenesis in vitro. *FEBS Lett.* 1997;418:6-10.
27. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E–deficient mice. *Circulation.* 1999;99:1726-1732.
28. Simonini A, Moscucci M, Muller DWM, et al. IL-8 is an angiogenic factor in human coronary atherectomy tissue. *Circulation.* 2000;101:1519-1526.
29. Dickinson CJ. Lung diseases associated with digital clubbing. *Clin Exp Rheumatol.* 1992;10(suppl 7):23-25.
30. Bigler FC. The morphology of clubbing. *Am J Pathol.* 1958;34:237-261.
31. Hirakata Y, Kitamura S. Elevated serum transforming growth factor α1 level in primary lung cancer patients with finger clubbing. *Eur J Clin Invest.* 1996;26:820-823.
32. Tisi GM, Conrique A, Barrett-Connor E, Grundy SM. Increased high density lipoprotein cholesterol in obstructive pulmonary disease (predominant emphysematous type). *Metabolism.* 1981;30:340-346.
33. Bolton CH, Mulloy E, Harvey J, Downs LG, Hartog M. Plasma and lipoprotein lipids and apolipoproteins AI, AII and B in patients with chronic airflow limitation. *J R Soc Med.* 1989;82:91-92.
34. Fekette T, Mosler R. Plasma lipoproteins in chronic obstructive pulmonary disease. *Horm Metab Res.* 1987;19:661-662.
35. Basili S, Ferroni P, Vieri M, et al. Lipoprotein(a) serum levels in patients affected by chronic obstructive pulmonary disease. *Atherosclerosis.* 1999;147:249-252.

©2004 American Medical Association. All rights reserved.

Downloaded From: http://archinte.jamanetwork.com/ on 11/29/2015